Sarepta Sarepta治疗公司面临一起集体诉讼, 指控在基因治疗索赔中存在证券欺诈。 Sarepta Therapeutics faces a class-action lawsuit for alleged securities fraud over gene therapy claims.

Sarepta治疗机构面临一项集体诉讼,指控其基因疗法ELEVIDYS的误导性陈述涉及证券欺诈,ELEVIDYS被用于杜尚肌肉萎缩症。 Sarepta Therapeutics faces a class-action lawsuit alleging securities fraud related to misleading statements about its gene therapy, ELEVIDYS, used for Duchenne muscular dystrophy. 诉讼声称该公司低估了安全风险,并误导投资者了解治疗的潜力和收入前景。 The lawsuit claims the company understated safety risks and misled investors about the therapy's potential and revenue outlook. 处理此案的律师事务所鼓励受影响的股东寻求有关其追偿权的信息。 Law firms handling the case encourage affected shareholders to seek information on their rights to recovery.